Подписаться
Anthony Joshua
Anthony Joshua
Kinghorn Cancer Centre, St Vincents Hospital, Sydney
Подтвержден адрес электронной почты в домене doctor.com - Главная страница
Название
Процитировано
Процитировано
Год
Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma
O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ...
New England Journal of Medicine 369 (2), 134-144, 2013
41652013
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
32972014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid, R Kefford, JS Weber, ...
The Lancet 384 (9948), 1109-1117, 2014
20762014
Enzalutamide with standard first-line therapy in metastatic prostate cancer
ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ...
New England Journal of Medicine 381 (2), 121-131, 2019
11762019
Association of pembrolizumab with tumor response and survival among patients with advanced melanoma
A Ribas, O Hamid, A Daud, FS Hodi, JD Wolchok, R Kefford, AM Joshua, ...
Jama 315 (15), 1600-1609, 2016
10862016
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ...
Annals of Oncology 30 (4), 582-588, 2019
7792019
Evaluation of immune-related response criteria and RECIST v1. 1 in patients with advanced melanoma treated with pembrolizumab
FS Hodi, WJ Hwu, R Kefford, JS Weber, A Daud, O Hamid, A Patnaik, ...
Journal of Clinical Oncology 34 (13), 1510, 2016
7312016
Programmed death-ligand 1 expression and response to the anti–programmed death 1 antibody Pembrolizumab in melanoma
AI Daud, JD Wolchok, C Robert, WJ Hwu, JS Weber, A Ribas, FS Hodi, ...
Journal of Clinical Oncology 34 (34), 4102, 2016
6182016
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ...
The Lancet 397 (10276), 797-804, 2021
5902021
Overall survival benefit with tebentafusp in metastatic uveal melanoma
P Nathan, JC Hassel, P Rutkowski, JF Baurain, MO Butler, M Schlaak, ...
New England Journal of Medicine 385 (13), 1196-1206, 2021
4772021
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial
RD Carvajal, JA Sosman, JF Quevedo, MM Milhem, AM Joshua, ...
Jama 311 (23), 2397-2405, 2014
4482014
Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma
C Robert, A Ribas, O Hamid, A Daud, JD Wolchok, AM Joshua, WJ Hwu, ...
Journal of clinical oncology 36 (17), 1668-1674, 2018
4402018
Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome
M Yoshimoto, AM Joshua, IW Cunha, RA Coudry, FP Fonseca, ...
Modern pathology 21 (12), 1451-1460, 2008
3372008
Pembrolizumab
L Khoja, MO Butler, SP Kang, S Ebbinghaus, AM Joshua
Journal for immunotherapy of cancer 3, 1-13, 2015
2832015
Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab
RW Joseph, J Elassaiss-Schaap, R Kefford, WJ Hwu, JD Wolchok, ...
Clinical Cancer Research 24 (20), 4960-4967, 2018
2572018
Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicentre, randomised trial (SUMIT)
RD Carvajal, S Piperno-Neumann, E Kapiteijn, PB Chapman, S Frank, ...
Journal of Clinical Oncology 36 (12), 1232-1239, 2018
2532018
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
TL Stockley, AM Oza, HK Berman, NB Leighl, JJ Knox, FA Shepherd, ...
Genome medicine 8, 1-12, 2016
2432016
Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
A Ribas, C Robert, FS Hodi, JD Wolchok, AM Joshua, WJ Hwu, JS Weber, ...
Journal of Clinical Oncology 33 (15_suppl), 3001-3001, 2015
2422015
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement
M Yoshimoto, AM Joshua, S Chilton-MacNeill, J Bayani, S Selvarajah, ...
Neoplasia 8 (6), 465-469, 2006
2362006
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
L Khoja, EG Atenafu, S Suciu, S Leyvraz, T Sato, E Marshall, U Keilholz, ...
Annals of Oncology 30 (8), 1370-1380, 2019
2202019
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20